H. Lundbeck A Logo

H. Lundbeck A

Develops and commercializes innovative therapeutics for brain diseases globally.

HLUN | CO

Overview

Corporate Details

ISIN(s):
DK0061804697 (+5 more)
LEI:
5493006R4KC2OI5D3470
Country:
Denmark
Address:
Ottiliavej 9, 2500 Valby
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

H. Lundbeck A/S is a global pharmaceutical company dedicated exclusively to developing and commercializing innovative treatments for brain diseases. The company's core focus is on neuroscience, engaging in the full value chain of research, development, manufacturing, and sales of therapeutics for psychiatric and neurological disorders. Its portfolio addresses a variety of conditions, including depression, migraine, and rare epilepsies. With a mission to advance brain health, Lundbeck markets its specialized products in numerous countries worldwide, managing operations from initial research to patient delivery.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-09-20 08:00
Regulatory News Service
English 146.2 KB
2025-09-20 08:00
Legal Proceedings Report
English 30.0 KB
2025-08-13 18:41
Interim Report
English 1.0 MB
2025-08-13 18:41
Earnings Release
English 32.1 KB
2025-08-13 18:35
Earnings Release
English 24.2 KB
2025-08-13 18:35
Earnings Release
English 129.5 KB
2025-02-21 13:27
Director's Dealing
English 124.1 KB
2025-02-21 13:27
Director's Dealing
English 29.9 KB
2025-02-05 16:40
Director's Dealing
English 134.1 KB
2025-02-05 16:40
Director's Dealing
English 96.6 KB
2025-02-05 07:46
Annual Report
English 6.4 MB
2025-02-05 07:46
Report Publication Announcement
English 2.9 KB
2025-02-05 07:46
Annual Report (ESEF)
English 13.1 MB
2025-02-05 07:24
Earnings Release
English 33.3 KB
2025-02-05 07:24
Earnings Release
English 443.0 KB

Automate Your Workflow. Get a real-time feed of all H. Lundbeck A filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for H. Lundbeck A via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

Company Country Ticker View
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland MAB
Magle Chemoswed Holding AB Logo
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden MAGLE
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany N/A
Marinomed Biotech AG Logo
Develops virus-blocking products & immunology therapies via proprietary technology platforms.
Austria MARI
Matricelf Ltd. Logo
Develops personalized 3D neural implants from patient cells to treat spinal cord injuries.
Israel MTLF
Median Diagnostics Inc. Logo
Manufactures veterinary IVD kits & raw materials to diagnose infectious animal diseases.
South Korea 233250
MediciNova,Inc. Logo
Developing small-molecule drugs for neurology, respiratory, and liver diseases.
Japan 4875
Medicon Hellas S.A. Logo
Develops, makes, and sells IVD products, analytical systems & software for healthcare providers.
Greece MEDIC

Talk to a Data Expert

Have a question? We'll get back to you promptly.